Repositioning Candidate Details
| Candidate ID: | R1009 |
| Source ID: | DB06423 |
| Source Type: | investigational |
| Compound Type: | biotech |
| Compound Name: | Endostatin |
| Synonyms: | Endostatins; Recombinant human endostatin |
| Molecular Formula: | -- |
| SMILES: | -- |
| DrugBank Description: | -- |
| CAS Number: | 187888-07-9 |
| Molecular Weight: | |
| DrugBank Indication: | Investigated for use/treatment in cancer/tumors (unspecified), macular degeneration, and diabetic retinopathy. |
| DrugBank Pharmacology: | -- |
| DrugBank MoA: | Endostatin is an endogenous antitumor protein. Endostatin is a 20-kDa C-terminal fragment derived from type XVIII collagen which inhibits cell proliferation and migration, and induces endothelial cell apoptosis and cell cycle arrest. It is proposed that endostatin's effects are due to inhibition of vascular endothelial growth factor (VEGF) tyrosine phosphorylation of KDR/F1k-1 (VEGF receptor 2), the cell surface receptor for VEGF. VEGF is an important mediator of angiogensis. Endostatin additionally blocks activation of extracellular signal related kinases, or ERK, protein 38 mitogen activated protein kinase, or p38 MAPK (signal transduction pathways involving kinases that couple growth factors to cell surface receptors), as well as focal adhesion kinase (p125FAK). Studies are being done to determine if endostatin has possible impact on other pathways, and may also target E-selectin and block activity of metalloproteinases 2, 9 and 13. There is further research into a possible mechanistic link involving endostatin's angiogenic and zinc binding ability. |
| Targets: | 72 kDa type IV collagenase; Matrix metalloproteinase-9; Collagenase 3; Focal adhesion kinase 1; E-selectin |
| Inclusion Criteria: | Therapeutic strategy associated |
